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Abstract: Inhaled therapy is key to the management of chronic obstructive pulmonary disease 
(COPD). New drugs and inhalers have recently been launched or will soon become available, 
and the expiry of patent protection covering several currently used inhaled bronchodilators 
and corticosteroids will be accompanied by the development of bioequivalent, generic inhaled 
drugs. Consequently, a broader availability of branded and generic compounds will increase 
prescription opportunities. Given the time course of COPD, patients are likely to switch drugs 
and inhalers in daily practice. Switching from one device to another, if not accompanied by 
appropriate training for the patient, can be associated with poor clinical outcomes and increased 
use of health care resources. In fact, while it seems reasonable to prescribe generic inhaled drugs 
to reduce costs, inadequate use of inhaler devices, which is often associated with a poor patient–
physician or patient–pharmacist relationship, is one of the most common reasons for failure to 
achieve COPD treatment outcomes. Further research is needed to quantify, as in asthma, the 
impact of inappropriate switching of inhalers in patients with COPD and show the outcomes 
related to the effect of using the same device for delivering inhaled medications.
Keywords: inhaled therapy, long-acting antimuscarinic agents, long-acting β
2
 agonists, inhaled 
corticosteroids, metered-dose inhalers, dry powder inhaler
Introduction
Inhaled therapy is key to the pharmacological management of patients with chronic 
obstructive pulmonary disease (COPD).1 Compared with oral or intravenous drugs, 
inhaled therapy quickly delivers the drug directly to the internal lumen of the air-
ways, thus lowering the dosage required and minimizing the side effects. The currently 
available inhaled drugs provide symptom relief, improve health status, enhance 
exercise capacity, and reduce the frequency and severity of COPD exacerbations.1
When the inhalation is performed correctly, all inhalers are equally effective, 
albeit at different doses.2,3 However, not all marketed devices fulfill patients’ needs in 
terms of reliability, portability, usability, ease of use, and dose tracking. In addition, 
appropriate positive reinforcement and feedbacks is not always available.4
Both experts’ group recommendation1 and documents from an international scien-
tific society5 emphasize the importance of close monitoring of inhalation technique 
and improving the efficiency of drug delivery. Although inhaled drug delivery is a 
painless and convenient choice, it presents some disadvantages. First, inadequate use 
of the inhaler is one of the most common reasons for failure to achieve COPD treat-
ment outcomes.6 Incorrectly performed inhalation maneuvers can hinder drug delivery 
and potentially reduce efficacy.3 Second, since inhaling medication is less manageable 
than oral administration7 and transdermal approaches,8 adherence may be affected. 
Furthermore, delivery of drugs by an inhaler requires the doctor to explain specific 
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techniques that must be monitored at subsequent visits. 
During treatment, patients may find it difficult to use the 
device, thus leading to underuse, misuse, or both.6 Improper 
use inevitably has consequences for both the patient’s health 
and the health system.9–11
A report from the European Respiratory Society and 
the International Society for Aerosols in Medicine recom-
mends that patients with stable disease should remain on 
their current inhaler rather than switching to a new one.5 In 
fact, switching devices could lead the patient to perform the 
inhalation technique incorrectly, owing to a lack of instruc-
tion and experience. The potential consequences include 
suboptimal drug administration, unsatisfactory adherence 
to treatment, and increased management costs.
Switching treatment in COPD: 
research findings
Data on switching of inhaled treatment in COPD and its 
effect on disease outcomes are lacking. In their analysis of 
the PHARMO database from 2002 to 2006, Penning-van 
Beest et al12 analyzed COPD patients starting treatment with 
long-acting antimuscarinic agents (LAMA), long-acting β
2
 
agonists (LABA), and the fixed dose combination (FDC) 
of LABA and inhaled corticosteroids (LABA-ICS FDC). 
The patients were included in the analysis only if they had 
been prescribed a long-acting drug within 6 months of their 
first prescription and had been followed for 3 years. In this 
trial, switching was defined as starting one of the other two 
long-acting inhaled drug classes after the last dispensing of 
the first drug. Switching from one inhaled device to another 
while maintaining the same drug was not investigated. A 
total of 7,548 patients were assessed. Persistent rates with 
initial monotherapy recorded at 1, 2, and 3 years were as 
follows: 25%, 14%, and 8% for LAMA; 21%, 10%, and 
6% for LABA; and 27%, 14%, and 8% for LAMA-ICS 
FDC. Among patients who did not continue LAMA alone 
for at least 1 year, 13% switched therapy and 15% added 
new drugs (essentially LABA-ICS FDC, which was also the 
option patients switched to in 74% of cases). Of the patients 
who did not continue LABA, 9% added therapy and 31% 
switched drugs, mostly to LABA-ICS FDC. In patients who 
did not continue with LABA-ICS FDC, 11% switched drugs. 
Of these, 60% switched to LAMA. The reasons for poor 
adherence to treatment or switching were not analyzed, but 
factors leading to switching and worthy of further investiga-
tion included poor efficacy, adverse events, dosing regimen, 
and device acceptability.
The preference and satisfaction, lung function and disease 
outcome13 of patients who switch from one device to another 
while maintaining the same drug has been explored14 but 
the impact of switching on cost and adherence remains 
unstudied.
Switching can lead to the use of multiple inhalers, and 
consequently a worsened adherence is expected. This asso-
ciation has been demonstrated even after controlling for 
proxy measures of COPD severity in patients on treatment 
with two or more long-acting inhaled drugs, namely, patients 
were 34% less likely to adhere to therapy and had a 40% 
higher treatment discontinuation rate than patients taking a 
single long-acting inhaled drug.15
COPD drugs: present and future
New drugs and inhalers for the treatment of COPD have 
recently been launched or are in the process of being launched 
in several European countries. Some pharmaceutical compa-
nies have invested directly or indirectly in research and devel-
opment of new inhalers, including the following: Respimat® 
Soft Mist™, which is the inhaler chosen by Boehringer 
Ingelheim (Ingelheim am Rhein, Germany) for administra-
tion of the LAMA tiotropium and the LABA olodaterol and 
their FDC; the ELLIPTA® dry powder inhaler (DPI), which 
is marketed by GlaxoSmithKline (Brentford, UK) for admin-
istration of the LAMA umeclidinium, the LABA vilanterol, 
the corticosteroid fluticasone furoate, and FDCs; Genuair®, 
which was acquired by AstraZeneca (London, UK) for 
administration of the LAMA aclidinium alone or in an FDC 
with the LABA formoterol; Breezhaler®, which is marketed 
by Novartis (Basel, Switzerland) for administration of the 
LABA indacaterol and the LAMA glycopyrronium alone 
or in an FDC; Nexthaler®, which was developed by Chiesi 
(Parma, Italy) for administration of the ICS-LABA FDC of 
beclomethasone dipropionate/formoterol, and combination 
with glycopyrronium; Spiromax®, which is produced by 
TEVA (Petah Tikva, Israel) for the administration of the ICS-
LABA FDC formoterol/budesonide, and salmeterol/flutica-
sone propionate; Forspiro®, selected by Sandoz (Holzkirchen, 
Germany) for the administration of the salmeterol/fluticasone 
propionate.
The expiry of the patent covering established inhaled bron-
chodilators, corticosteroids, and their FDCs has contributed 
to or will promote the development of generic inhaled drugs 
that are bioequivalent to the original branded medications.16 
While generic inhaled medications have the same chemi-
cal structure as branded ones, they are not always delivered 
using the same device, which is often protected by ongoing 
patents. The European Medical Agency guideline approves the 
generic version of an inhaler product based on in vitro assess-
ment if the product meets established criteria, thus enabling 
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interchangeability.17 When in vitro comparability is not proven, 
it is necessary to perform a lung deposition analysis, which is 
sometimes accompanied by pharmacodynamics and/or clinical 
testing. Unlike oral or injected drugs, the European Medical 
Agency does not consider inhaled drugs as generic agents, but 
as hybrids.17 The US Food and Drug Administration (FDA) 
defines inhaled drugs as “therapeutic and diagnostic products 
that combine drugs, devices, and/or biological products”.18 
Therefore, given that one device differs from another, devel-
opment of a generic is very challenging.19 In fact, the FDA 
requires manufacturers to demonstrate delivery to the lungs, 
systemic exposure, and device equivalence of both generic and 
branded products.19 The aforementioned rules have discour-
aged applications for generics in the USA, although there are 
many older pressurized metered-dose inhalers on the market 
without patent or exclusivity protection.
Switching possibilities: the Italian 
case history
The Italian Drug Agency has approved 17 different agents 
or their FDCs for the treatment of COPD.20 The list com-
prises three short-acting β
2
 agonists (salbutamol, terbutaline, 
fenoterol), four LABA (salmeterol, formoterol, indacaterol, 
olodaterol), three LAMAs (tiotropium, aclidinium, 
glycopyrronium), four FDCs containing a β
2
 agonist and an 
ICS (salbutamol/beclomethasone, formoterol/budesonide, 
salmeterol/fluticasone propionate, vilanterol/fluticasone 
furoate), two fixed combinations of a short-acting β
2
 
agonist and a short-acting antimuscarinic antagonist 
(fenoterol/ipratropium bromide, salbutamol/ipratropium 
bromide), and one FDC of a LABA and a LAMA 
(indacaterol/glycopyrronium). The launch of the FDCs 
umeclidinium/vilanterol, formoterol/aclidinium, formoterol/
beclomethasone, salmeterol/fluticasone propionate, and 
olodaterol/tiotropium under different brand names is envis-
aged for the second semester of 2015 or the first semester 
of 2016.
Considering all drugs already approved by the Italian Drug 
Agency, 41 different brands are now available and a total of 
13 different inhaled devices are now on the market. Match-
ing compounds, devices, and types of manufacture enable 
physicians to prescribe a series of products (one drug or a 
combination of drugs) with 48 possible switches (Table 1).
Since several patented single drugs or drug combi-
nations have expired or will soon expire, the advent of 
generic compounds will increase prescription opportunities. 
For example, formoterol is available in Italy under 12 brand 
names with 5 different inhalers, providing a total of 21 
Table 1 Licensed and launched soon inhaled drugs for COPD treatment in Italy
Drug Formulation Device Company (international headquarters  
location)
SABA
Salbutamol Pressurized suspension MDI Sandoz (Holzkirchen, Germany)
Pressurized suspension MDI GlaxoSmithKline (Brentford, UK)
Terbutaline Multidose dry powder Turbohaler AstraZeneca (London, UK)
Fenoterol Pressurized solution MDI Boehringer Ingelheim (Ingelheim am Rhein, Germany)
LABA
Salmeterol Pressurized suspension MDI Dompè (Milan, Italy)
Multidose dry powder Diskus® Dompè
Multidose dry powder Diskus® Lusofarmaco (Milan, Italy)
Pressurized suspension MDI Lusofarmaco
Pressurized suspension MDI GlaxoSmithKline
Multidose dry powder Diskus® GlaxoSmithKline
Formoterol fumarate Multidose dry powder Pulvinal® Chiesi (Parma, Italy)
Pressurized solution MDI Chiesi
Pressurized solution MDI Biofutura (Milan, Italy)
Single-dose dry powder Aerolizer® Rottapharm (Monza, Italy)
Pressurized solution MDI Novartis (Basel, Switzerland)
Single-dose dry powder Aerolizer® Novartis
Single-dose dry powder Aerolizer® euroGenerici (Milan, Italy)
Multidose dry powder Novolizer® Meda Pharma (Solna, Sweden)
Single-dose dry powder Aerolizer® S.F. group s.r.l (Pescara, Italy)
Single-dose dry powder Aerolizer® Italchimici (Pomezia, Italy)
Single-dose dry powder Aerolizer® Genetic S.P.A. (Fisciano, Italy)
Pressurized solution MDI Caber (Rome, Italy)
(Continued)
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prescribing possibilities. Therefore, switching drugs and/or 
inhalers could generate hundreds of potential treatment pos-
sibilities in daily clinical practice (Figure 1).
Potential impact of switching 
inhaled drugs on costs
No clear evidence from real-life research is available on the 
economic effects of switching drugs in COPD. However, when 
a switch of inhaler is envisaged, it is necessary to take account of 
both direct and indirect costs, such as those generated by potential 
worsening of the disease, impact on health-related quality of life, 
increased or reduced administration of other treatments, and use 
of health care resources. It is noteworthy that the cost of emer-
gency treatment is greater than that of planned treatment.21
Measures to contain prescription costs are becoming 
increasingly common in many countries. The extensive 
Table 1 (Continued)
Drug Formulation Device Company (international headquarters  
location)
Multidose dry powder Pulvinal Caber
Multidose dry powder Turbohaler AstraZeneca
Indacaterol Single-dose dry powder Breezhaler® Chiesi
Single-dose dry powder Breezhaler Novartis
Olodaterol Soft mist inhaler Respimat® Boehringer Ingelheim
LAMA
Tiotropium bromide Single-dose dry powder Handihaler® Boehringer Ingelheim
Soft mist inhaler Respimat Boehringer Ingelheim
Aclidinium bromide Multidose dry powder Genuair® Guidotti (Pisa, Italy)
Multidose dry powder Genuair AstraZeneca
Glycopyrronium bromide Single-dose dry powder Breezhaler Novartis
Single-dose dry powder Breezhaler Biofutura
Umeclidinium bromide Single-dose dry powder eLLIPTA® GlaxoSmithKline
SABA + SAMA
Fenoterol + ipratropium Pressurized solution Metered dose inhaler Boehringer Ingelheim
Salbutamol + ipratropium Pressurized solution Metered dose inhaler valeas (Milan, Italy)
LABA + LAMA
Vilanterol + umeclidinium 
bromide
Multidose dry powder ELLIPTA GlaxoSmithKline
Multidose dry powder ELLIPTA Menarini
Indacaterol + glycopyrronium bromide Single-dose dry powder Breezhaler Novartis
Single-dose dry powder Breezhaler Biofutura
Formoterol + aclidinium bromide Multidose dry powder Genuair AstraZeneca
Multidose dry powder Genuair Guidotti & Malesci
Olodaterol + tiotropium bromide Soft mist inhaler Respimat Boehringer Ingelheim
LABA + ICS FDC
Salbutamol + beclomethasone Pressurized suspension Metered dose inhaler Chiesi
Pressurized suspension jet MDI Jet® Chiesi
Salmeterol + fluticasone propionate Multidose dry powder Diskus Menarini
Dual blister dry powder elpenhaler® Caber
Multidose dry powder Diskus GlaxoSmithKline
Multidose dry powder Forspiro® Sandoz
Formoterol fumarate + budesonide Multidose dry powder Turbohaler AstraZeneca
Multidose dry powder Turbohaler Sigma-Tau (Pomezia, Italy)
Multidose dry powder Turbohaler AstraZeneca
Breath-actuated dry 
powder
Spiromax® TevA (Petah Tikva, Israel)
vilanterol + fluticasone furoate Multidose dry powder eLLIPTA GlaxoSmithKline
Multidose dry powder eLLIPTA Menarini (Firenze, Italy)
Formoterol fumarate + 
beclomethasone
Multidose dry powder Nexthaler® Dompè
Multidose dry powder Nexthaler Chiesi
Multidose dry powder Nexthaler Novartis
Notes: Non-bold text indicates the inhaled drugs that are licensed. Bold text indicates the inhaled drugs that will be launched soon.
Abbreviations: COPD, chronic obstructive pulmonary disease; FDC, fixed dose combination; ICS, inhaled corticosteroids; LAMA, long-acting antimuscarinic agents; LABA, 
long-acting β2 agonists; MDI, metered-dose inhaler; SABA, short-acting β2 agonists; SAMA, short-acting antimuscarinic antagonist.
International Journal of COPD 2015:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2605
Switching treatments in COPD
use of generics may enable substantial savings to be made, 
theoretically at no detriment to patient care. Thus, switching 
from branded inhaled drugs to cheaper generic ones may 
reduce the costs of treating patients with COPD.22
The rules on substitution of branded drugs with generic 
drugs vary from country to country.22 In Germany and 
Finland, for example, substitution with generic drugs is 
mandatory by law, while in the UK and the Netherlands, 
substitution is permitted if generic names are used on the 
prescription. In this case, continued use of a specific device is 
guaranteed by the phrase “medical necessity” on the pre-
scription. Similarly, in Italy, pharmacists are free to switch 
Figure 1 Potential switching possibilities in COPD inhaled treatment.
Abbreviations: COPD, chronic obstructive pulmonary disease; FDC, fixed dose combination; ICS, inhaled corticosteroids; LABA, long-acting β2 agonists; LAMA, long-acting 
antimuscarinic agents.
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patients with respiratory disease from a branded drug to a 
generic drug, unless the prescription states that the branded 
drug must not be switched. However, patients who refuse 
to substitute a branded product with a generic one must pay 
the difference in cost. The case of France deserves special 
mention, since there are no inhaled generics to replace 
branded products, although some pressurized metered-dose 
inhalers can be considered interchangeable. Since different 
devices require different techniques for use, switching could 
lead to poor inhalation procedures unless patients receive 
appropriate training. If appropriate training is not provided, 
patients may find it difficult to operate the device and may 
even stop using it.23 Research in patients with asthma has 
shown that appropriate instruction does not lead to differ-
ences in clinical outcomes, whereas a switch without previous 
consultation with the patient leads to poorer disease control.24 
Optimization of current pharmacotherapy (eg, close moni-
toring of inhalation technique and medication adherence) 
is cost-effective, even in COPD, and should be considered 
before the patient is prescribed new therapy.25
Potential impact of switching 
inhaled drugs on adherence 
to treatment
Decreased adherence, whether intentional or unintentional, 
is a common outcome of switching.26 Unintentional non-
adherence may occur because of poor handling technique, 
critical handling errors, an inability to recall consultations, 
and environmental constraints such as costs of or difficulty 
obtaining prescriptions. Patients may intentionally stop using 
an inhaler that they themselves did not choose. Patients do not 
have equal preferences for different inhalers,27 and in most 
cases, the higher the patient’s satisfaction with the device, 
the greater the likelihood of good adherence and, therefore, 
more favorable outcomes.28 The efficiency of drug delivery 
can also be affected by patient preference, which, in turn, 
affects adherence to treatment and subsequent long-term 
control of the disease. DPIs, in particular, can vary markedly 
in design and method of operation,29 potentially leading to 
handling errors.30 When long-term users of branded inhaled 
drugs are dispensed generics delivered by a different inhaler, 
the potential change in taste/sensation could reduce their con-
fidence in the efficacy of the generic drug and thus increase 
the risk of poor adherence and exacerbation.23
A structured questionnaire administered to physicians 
in France, Germany, and the UK showed that only 9% of 
those interviewed thought that DPIs were interchangeable, 
while the remainder considered that these inhalers were not 
interchangeable.31 In addition, over 90% of the physicians 
thought that interchangeability of DPIs would have a negative 
impact on adherence and inhaler handling and the patient’s 
willingness to use the inhaler if he/she was not involved in 
the choice of the device.
Patient training: a key component
A survey of health care professionals in the UK32 found that 
the vast majority were concerned about potential problems 
arising from prescriptions that do not specify the inhaler to 
be dispensed. In the survey by Price,31 46% of the physicians 
interviewed were aware of patients who had received a dif-
ferent inhaler, the consequences of which included confusion, 
ineffective inhalation technique, and the need to reissue pre-
scriptions. In a survey conducted in the primary and secondary 
care setting in three European countries, over one-half of all 
the respondents reported problems with the inhaler as one of 
the main reasons for switching inhaled therapy. Most physi-
cians were opposed to substitution of one DPI for another if 
the pharmacist did not consult the patient and/or the physi-
cian. These findings indicate that health care professionals 
perceive inhalers as different and not interchangeable, with 
physicians opposed to substitution of one device by another 
without consultation with the patient and appropriate training. 
In addition, health care professionals believe that involving the 
patient in the choice of inhaler plays a key role in adherence. 
Interventions focused on inhalation technique and adherence 
to maintenance therapy in a community pharmacy setting 
showed that a planned intervention can improve drug therapy 
in patients with COPD and reduce hospitalization rates.33
COPD recommendations state that, regardless of the 
device prescribed, patients should receive appropriate train-
ing and undergo regular assessment of inhalation technique.1 
However, the guidelines provide no information on how to 
provide training when a patient’s branded drug is switched to 
a generic alternative, particularly if the patient is not aware of 
the switch. Consequently, patients do not receive counseling 
about the new medication and device from their health care 
provider, resulting in poor inhalation technique and loss of 
disease control. This finding is supported by evidence in 
asthma,23,24 while no specific trials have been developed for 
COPD. Nevertheless, given the disease course and treatment 
of both diseases, it seems reasonable to apply the findings for 
one disease to the other. Switching without the patient’s con-
sent may not result in cost savings, because of more frequent 
visits to the clinic for training and support and negative 
impacts on disease outcomes, resulting in higher short- and 
long-term health care costs. Although patient education and 
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involvement in treatment decisions can improve adherence,29 
the multidimensional nature of adherence means that no 
single intervention or strategy per se can enhance it. All 
those involved in the process (government authorities, patient 
organizations, scientific societies, stakeholders, and others) 
must cooperate to develop a combined action plan based on 
the individual needs of the patient.34
Conclusion
Switching drugs and inhalers warrants special attention in 
COPD management. Caution should be exercised before 
switching from one device to another, and both the physician 
and the patient should be involved in the decision to switch. 
When a generic inhaler replaces a branded inhaler, patients 
should be willing to use the new inhaler and receive adequate 
training.35 Importantly, the responsibility for such training 
needs to be clarified, because physicians may not be aware 
that a prescribed branded inhaler has been replaced with a 
generic one at the pharmacy.36
In conclusion, the pressure to reduce costs and ensure 
efficient allocation of limited health care resources means that 
any effort to improve adherence could generate cost savings 
resulting from decreased demand for health care services. 
In contrast, savings achieved in purchase costs could gener-
ate a greater net loss arising from increased consumption of 
health care resources to treat worsening of COPD symptoms 
and exacerbations.
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